November 20, 2017
Investors should pause and reflect on gains and losses if risks hibernate in a holiday-shortened week
Many ask, why I continue – as a “true’ believer in the science, someone with the institutional history has to keep the record straight …
My issue is the “posers” who inflate the hope and possibility of breakthroughs while “skimming” the G&A and cash positions, one example of a few - Biostage (BSTG)
Pre-open trading indications: 6 SELLs and 3 BUYs:
Can’t read because of no subscription - you’re missing situational awareness and the most trustworthy source of independent insight!
October 29, 2017
For continued access to what one industry CEO calls the “bible” for smart investing in the RegMed, gene and cell therapy sector, click the link:
Learn who is stumbling and what the mumbling means!
October 23, 2017
QURE was priced at $18.25 per share
October 13, 2017
Are day traders ready for the filed 8-K as BSTG conducted a reduction in headcount …
November 20, 2017
The iShares Nasdaq Biotechnology (IBB -0.93%) and SPDR S&P Biotech (XBI -0.69%) were down
Low volume and no real news causes more than a little selling for profit-taking
A lot of hands are out, waiting for a payday while some fingers are readying a push of a turkey button i.e. get me out’a here!
Daily pre-open indications: 5 hits and 4 miss
How right does one have to be? You could and should be reading this review of the day’s share pricing activity?
Is the truth so hard to fathom – that’s why my readership has grown exponentially!
November 16, 2017
AXGN is down -$2.95 or -11.85% after closing at $24.90
November 14, 2017
Thirty four (34) as of today ... so far Financial results also known as (AKA) earnings are a ‘scorecard’ of public stem, cell, gene and regenerative therapy's companies.
October 30, 2017
NASDAQ shares drop -$0.31 or -15.98% to $1.66
The process of calling out our grading of covered companies to rank and review the facts in evidence together with analysis, opinion and objective recommendation.